{"log_id": 5508449693581037100, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.010634, "average": 0.946875, "min": 0.398545}, "location": {"width": 1002, "top": 106, "height": 56, "left": 87}, "words": "能需要减少瑞格列奈的用药剂量在同一研究中,瑞格列奈与吉非贝和CYP3A4排制剂伊曲康唑合用显示出"}, {"probability": {"variance": 0.002991, "average": 0.97155, "min": 0.726144}, "location": {"width": 728, "top": 161, "height": 48, "left": 88}, "words": "更强的降糖作用,瑞格列奈AUC增加19.4倍,半衰期从1.3小时延长到6.1小时"}, {"probability": {"variance": 0.010734, "average": 0.953468, "min": 0.447111}, "location": {"width": 960, "top": 202, "height": 52, "left": 129}, "words": "甲氧苄啶(每日两次,每次160mg)是一种弱CYP2C8抑制剂,与瑞格列奈(单剂0.25mg)同服,可使"}, {"probability": {"variance": 0.010311, "average": 0.953219, "min": 0.452671}, "location": {"width": 1001, "top": 248, "height": 55, "left": 88}, "words": "格列奈AUC,Cma、和生物半衰期有轻微的增加(分别为1.6倍,1.4倍和1.2倍),血水平增加无明显的统计学"}, {"probability": {"variance": 0.034563, "average": 0.885025, "min": 0.352577}, "location": {"width": 1001, "top": 296, "height": 54, "left": 89}, "words": "异这些缺少药效学结果的数据系根据瑞格列奈低剂量治疗获得。尚无瑞格列剂高于0.25mg与甲"}, {"probability": {"variance": 0.021117, "average": 0.916885, "min": 0.355801}, "location": {"width": 997, "top": 342, "height": 55, "left": 93}, "words": "卡啶剂高于320rug的合用安全性数据,因此应避免将瑞格列袋与甲氧卡氨嘧啶合用。如果必须合,严密"}, {"probability": {"variance": 2.6e-05, "average": 0.996842, "min": 0.978572}, "location": {"width": 419, "top": 404, "height": 41, "left": 89}, "words": "监测患者的血糖水平,并进行严密的临床监测"}, {"probability": {"variance": 0.010108, "average": 0.962076, "min": 0.482019}, "location": {"width": 953, "top": 438, "height": 52, "left": 130}, "words": "利福平是一种CYP3A4强诱导剂,也是CYP2C8诱导剂,在瑞格列奈的代谢过程中同时起诱导和制作用"}, {"probability": {"variance": 0.003673, "average": 0.962841, "min": 0.774919}, "location": {"width": 999, "top": 484, "height": 54, "left": 93}, "words": "使用利福平(600mg)先期治疗7天,然后与瑞格列奈(单剂4mg)在第7大时台用,AUC降低了50%这是"}, {"probability": {"variance": 0.022432, "average": 0.934675, "min": 0.37332}, "location": {"width": 997, "top": 532, "height": 52, "left": 93}, "words": "诱导和制作用的共同结果在最后一次服用利醋24小时后服用瑞格列,瑞格列的AUC降低了80%单"}, {"probability": {"variance": 0.003041, "average": 0.967956, "min": 0.848168}, "location": {"width": 123, "top": 602, "height": 27, "left": 90}, "words": "独诱导作用)"}, {"probability": {"variance": 0.006896, "average": 0.969365, "min": 0.534145}, "location": {"width": 927, "top": 626, "height": 49, "left": 134}, "words": "利福平与瑞格列奈合用可能会降低瑞格列奈的用药剂量,应严密监测患者在开始使用利福平(快速排制"}, {"probability": {"variance": 0.01118, "average": 0.958396, "min": 0.470081}, "location": {"width": 1003, "top": 672, "height": 53, "left": 92}, "words": "增加剂量(混合抑制和诱导)和停用利福平(单独诱导)以及停用利福平约1周后,其诱导作用消失时的血糖水"}, {"probability": {"variance": 0.022057, "average": 0.933488, "min": 0.448017}, "location": {"width": 414, "top": 735, "height": 38, "left": 94}, "words": "平,并根据血糖水平调节格列奈的使用剂量"}, {"probability": {"variance": 0.005904, "average": 0.95732, "min": 0.653763}, "location": {"width": 807, "top": 772, "height": 48, "left": 136}, "words": "克拉霉素是一种CYP3A4强抑制利,以每口两次,每次250m剂量与瑞格列奈(单剂0.2"}, {"probability": {"variance": 0.069963, "average": 0.830876, "min": 0.372903}, "location": {"width": 102, "top": 773, "height": 23, "left": 993}, "words": "同,使"}, {"probability": {"variance": 0.019513, "average": 0.903361, "min": 0.3805}, "location": {"width": 981, "top": 816, "height": 53, "left": 94}, "words": "格列奈的暴露量有微弱的增加AUC增加4倍,Cm增加1.7倍)如清胰岛素AUC平均增值增加5倍C"}, {"probability": {"variance": 0.02922, "average": 0.906056, "min": 0.524702}, "location": {"width": 115, "top": 889, "height": 24, "left": 96}, "words": "增1.0倍)"}, {"probability": {"variance": 0.013784, "average": 0.927863, "min": 0.531808}, "location": {"width": 961, "top": 911, "height": 52, "left": 135}, "words": "服用瑞格列奈(单次给药4mg)的同时服用CYP3A4强抑制剂康唑(每日200mg),可在一定范周增"}, {"probability": {"variance": 0.013056, "average": 0.937914, "min": 0.401395}, "location": {"width": 675, "top": 966, "height": 48, "left": 94}, "words": "瑞格列奈的暴露量(AUC增加1.2倍,Cm增加1.6倍),血糖变化低于8"}, {"probability": {"variance": 0.027351, "average": 0.916692, "min": 0.372668}, "location": {"width": 965, "top": 1008, "height": 53, "left": 134}, "words": "瑞格列奈与米替、硝苯地平或辛伐他汀合用,所有CYP3A4作用底物均显著改变瑞格列奈的药代的"}, {"probability": {"variance": 3e-06, "average": 0.998299, "min": 0.995343}, "location": {"width": 84, "top": 1081, "height": 26, "left": 97}, "words": "力学参数"}, {"probability": {"variance": 0.008628, "average": 0.952283, "min": 0.605284}, "location": {"width": 951, "top": 1104, "height": 50, "left": 138}, "words": "在健康志愿者中进行的药物相互作用研究发现,瑞格列泰对地高辛、茶碱和法华林的药代动力学特性无影晌"}, {"probability": {"variance": 0.021306, "average": 0.921887, "min": 0.529735}, "location": {"width": 518, "top": 1163, "height": 39, "left": 97}, "words": "此在与瑞格列东联合使用时,无需调整这些药物的削量"}, {"probability": {"variance": 0.029265, "average": 0.908796, "min": 0.374109}, "location": {"width": 960, "top": 1196, "height": 55, "left": 138}, "words": "在健康志愿者中开展的一项药代动力学研究表明,台用口服避孕药(乙炔一炔孕酮然会缩"}, {"probability": {"variance": 0.012804, "average": 0.959898, "min": 0.362907}, "location": {"width": 1006, "top": 1243, "height": 55, "left": 96}, "words": "瑞格列奈的达峰时间,但不会改变瑞格列奈的总生物利用度至相关床范围,瑞格列奈对左炔诺孕酮的生物利用"}, {"probability": {"variance": 9.2e-05, "average": 0.993694, "min": 0.959701}, "location": {"width": 666, "top": 1300, "height": 46, "left": 96}, "words": "度没有具临床意义的影响,但不能排除对乙炔雌二醇的生物利用度的影响"}, {"probability": {"variance": 0.003273, "average": 0.969715, "min": 0.76232}, "location": {"width": 459, "top": 1353, "height": 40, "left": 145}, "words": "下列药物可能增强和/或延长瑞格列奈的降血糖作用"}, {"probability": {"variance": 0.022777, "average": 0.924392, "min": 0.444781}, "location": {"width": 876, "top": 1391, "height": 50, "left": 143}, "words": "古非贝齐,克拉霉素,酮康唑,伊曲康晔,甲低苄啶,其他类型抗糖尿病药物,单按氧化酶制"}, {"probability": {"variance": 0.012373, "average": 0.957114, "min": 0.451191}, "location": {"width": 809, "top": 1442, "height": 48, "left": 102}, "words": "非选择性β受体阻滞剂,血管紧张素转换酶(ACE)抑制剂,酒精以及促合成代谢的激素"}, {"probability": {"variance": 0.003372, "average": 0.970832, "min": 0.808234}, "location": {"width": 354, "top": 1500, "height": 36, "left": 166}, "words": "列药物可能诚弱瑞格列奈的降血糖作用"}, {"probability": {"variance": 0.014645, "average": 0.931885, "min": 0.467078}, "location": {"width": 962, "top": 1534, "height": 51, "left": 143}, "words": "口服避孕药,利平,苯巴比要和卡马西平,噻嗪类药物,皮质激素,达那唑,甲状腺激素,奥曲肽利拟交"}], "language": 3}